PKG II effectively reversed EGF-induced protein expression alterations in human gastric cancer cell lines

Area of Science:

• Oncology
• Molecular Biology
• Cell Signaling

Background:

• Epidermal growth factor receptor (EGFR) is crucial in gastric cancer (GC) progression.
• Type II cGMP-dependent protein kinase (PKG II) previously showed potential to inhibit the EGF-EGFR pathway in GC cells.
• The precise mechanisms by which PKG II exerts its anti-cancer effects require elucidation.

Purpose of the Study:

• To investigate the molecular mechanisms underlying the anti-cancer effects of PKG II in human gastric cancer cells.
• To identify specific proteins affected by PKG II activation in the context of EGFR signaling.

Main Methods:

• Human GC cell line AGS was treated with an adenoviral construct for PKG II (Ad-PKG II) and 8-pCPT-cGMP.
• Two-dimensional electrophoresis (2-DE) was employed to analyze global protein expression changes.
• Western blotting and gene silencing (MarvelD3) were used to validate specific protein roles.

Main Results:

• PKG II activation reversed protein expression changes induced by EGF treatment in GC cells.
• PKG II normalized the expression of far upstream element-binding protein 1 (FUBP1) and MarvelD3, which were altered by EGF/EGFR signaling.
• Silencing MarvelD3 diminished the inhibitory effect of PKG II on EGF-stimulated cell migration.

Conclusions:

• PKG II exerts inhibitory effects on gastric cancer progression.
• The anti-cancer mechanism of PKG II involves the modulation of specific protein expression, including MarvelD3.
• MarvelD3 plays a partial role in mediating the anti-migratory effects of PKG II in response to EGF signaling.